ArticleCell host & microbe2019
Colitis-Induced Th17 Cells Increase the Risk for Severe Subsequent Clostridium difficile Infection.
Article in Cell host & microbe, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 101 citations in OpenAlex.
- Unveiling the Th17/Treg imbalance: a key player inGut microbes · 2026Article
- Taxifolin impairs colonization ofMicrobiology spectrum · 2026Article
- Balancing act of cytokines in controlling the severity ofInfection and immunity · 2026Review
- Phase variable colony morphotypes ofInfection and immunity · 2026Article
- Propensity-Matched Case Control Study of Anti-Interleukin-23 Therapies in Clostridioides difficile Infection.Research square · 2026Article
- An anaerobic pathogen rewires host metabolism to fuel oxidative growth in the inflamed gut.Cell · 2026Article
- Association of circulating leptin concentration with the risk of Clostridium difficile colitis and exploration of their associated mediators: A mendelian randomisation study.Journal, genetic engineering & biotechnology · 2026Article
- Aged Gut Microbiota Induces Mucosal Transcriptional Dysregulation, Impairing Immune Surveillance.Aging cell · 2026Article
- REGULATION OF COLONIC MACROPHAGES AND TYPE-17 AND REGULATORY T CELLS IN DSS-COLITIS BY IBD-ASSOCIATED TRANSCRIPTION FACTOR, CREM.bioRxiv : the preprint server for biology · 2026Article
- Observational
- Phase variable colony morphotypes ofbioRxiv : the preprint server for biology · 2026Article
- Anti-interleukin-23 treatment linked to improvedGut microbes · 2025Article
- Clostridioides difficile toxin A and toxin B inhibit toxin-specific adaptive immune responses through glucosyltransferase-dependent activity.Mucosal immunology · 2025Article
- Immune Aspects of Clostridioides difficile Infection and Vaccine Development.Infectious disease clinics of North America · 2025Review
- The interplay between host immunity andmBio · 2025Review
- The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection.Nature reviews. Gastroenterology & hepatology · 2025Review
- Article
- IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity.The Journal of clinical investigation · 2025Article
- Mechanisms ofFrontiers in cellular and infection microbiology · 2025Review
- IL-33 protects from recurrentbioRxiv : the preprint server for biology · 2024Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Clostridium difficile infection (CDI) is the number one hospital-acquired infection in the United States. CDI is more common and severe in inflammatory bowel disease patients. Here, we studied the mechanism by which prior colitis exacerbates CDI. Mice were given dextran sulfate sodium (DSS) colitis, recovered for 2 weeks, and then were infected with C. difficile. Mortality and CDI severity were increased in DSS-treated mice compared to controls. Severe CDI is dependent on CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.